Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12283230 | 0.88 | CSNK2A2 (0.67) | CSNK2A2CSNK2A1CSNK1DRIPK1STK17B | |
| SCHEMBL12283706 | 0.83 | CSNK2A2 (0.95) | CSNK2A2CSNK2A1 | |
| SCHEMBL14654945 | 0.82 | CSNK2A2 (0.53) | CSNK2A2CSNK2A1RIPK1 | |
| SCHEMBL12537596 | 0.73 | NTRK1 (0.41) | CSNK2A2CSNK2A1CSNK1D | |
| SCHEMBL29799705 | 0.71 | CSNK1D (0.48) | CSNK2A2CSNK2A1CSNK1DSTK17BSTK17A | |
| SCHEMBL21366005 | 0.71 | CSNK1D (0.48) | CSNK2A2CSNK2A1CSNK1DSTK17BSTK17A | |
| SCHEMBL19279707 | 0.70 | CSNK2A2 (0.39) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635296 | 0.68 | CSNK2A2 (0.68) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635298 | 0.68 | CSNK2A2 (0.68) | CSNK2A2CSNK2A1 | |
| SCHEMBL14635504 | 0.68 | CSNK2A2 (1.00) | CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | CSNK2A2 123/4885CSNK2A1 84/4885CSNK1D 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.